I don't know what's going to happen to UnitedHealth Group
Revenue for this fourth quarter rose more than 14%, and operating earnings climbed 20%, leading to yet another expansion in the operating margin. Sharper-eyed Fools might notice that the margin slipped a bit from the third quarter, but this period included expenses related to the launch of the much-ballyhooed Medicare Part D drug benefit program. At the bottom line, earnings per share rose 20% on an as-reported basis.
Well-controlled expenses have been a big theme here for a while and will, I have to think, become even more important in the future. At some point, this drag race between premiums and medical costs has to end, or else we'll all be paying 200% of our incomes on health care. So with UnitedHealth's advantage of size and scale (it can spread costs across a wider base and have a lot more leverage with health providers), it should be in a good position to keep margins strong and costs to the consumer/client more reasonable.
That's not to say it's easy sledding from here on out. Rivals great and small, like Aetna
The fears about what could happen in the industry aren't the reason I don't own this stock. The reason is price. As I see it (or, rather, model it), the stock is fairly valued. There's nothing wrong with that -- I hold a few "fairly priced" stocks in my portfolio today -- and I'm not suggesting anybody should sell out. But given that I'm a charter member of the cult of margin of safety (that is, buying stocks at a discount to what you think they're worth), I'm going to sit on the sidelines for now.
For more related Foolishness:
UnitedHealth and Coventry are Motley Fool Stock Advisor selections. To see more of the stocks Tom and David Gardner have recommended, take Stock Advisor for a free, no-risk test drive. You'll be happy you did.
Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).
More from The Motley Fool
GM Proved Doubters Wrong in 2017 With a Strong Crossover Lineup
GM surprised the market when it announced strong guidance thanks to a revamped line of crossovers and SUVs. Better still, it delivered on the promises.
Ford's Behind-the-Scenes Focus on Data
Ford’s recent partnerships and small-scale tests could bode well for the future.
Ford's Tumultuous 2017
Ford’s stock languished behind GM throughout 2017. Will 2018 be a turnaround year?